Skip to main content
Figure 1 | Respiratory Research

Figure 1

From: Validation of a guideline-based composite outcome assessment tool for asthma control

Figure 1

Study design for (a) Strata 1 and 2, and (b) Stratum 3. Following a 4-week run-in period, patients were randomised to receive either salmeterol/fluticasone propionate (SFC) or fluticasone propionate (FP) alone and stratified according to inhaled corticosteroid (ICS) use during the 6 months before screening: Stratum 1, no ICS; Stratum 2, 500 μg beclometasone dipropionate daily or equivalent; or Stratum 3, > 500–1000 μg beclometasone dipropionate daily or equivalent.

Back to article page